<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04976777</url>
  </required_header>
  <id_info>
    <org_study_id>1491-801-007</org_study_id>
    <nct_id>NCT04976777</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate an Updated Dexamethasone Intravitreal (Into the Eye) Applicator in Adult Participants With Macular Edema Due to Diseases of the Retina</brief_title>
  <official_title>Evaluation of an Updated Dexamethasone Posterior Segment Drug Delivery System Applicator in Participants With Macular Edema Due to Retinal Diseases Incorporating Versions 1.0 and 2.0</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) Applicator is used to&#xD;
      deliver an implant with medicine to the eye. AbbVie is updating the DEX PS DDS Applicator.&#xD;
      This purpose of this study is to show that the updated DEX PS DDS Applicator works in adult&#xD;
      participants with macular edema due to retinal diseases.&#xD;
&#xD;
      The DEX PS DDS is approved for the treatment of macular edema. Participants will be placed&#xD;
      into 1 of 2 groups, called treatment arms. Each group receives a different treatment. Around&#xD;
      54 adult participants with macular edema will be enrolled in the study in approximately 7-10&#xD;
      sites in the United States.&#xD;
&#xD;
      Participants will receive a single intravitreal (into the eye) administration of DEX PS DDS&#xD;
      implant using either the currently-approved DEX PS DDS Applicator or the the updated&#xD;
      Applicator. The participants will be observed for a duration of 7 days, with the DEX PS DDS&#xD;
      implant received on day 1 and follow-up through day 7.&#xD;
&#xD;
      There may be higher treatment burden for participants in this trial compared to their&#xD;
      standard of care. The updates being evaluated in this study are related to the DEX PS DDS&#xD;
      Applicator only, with the safety and efficacy of the DEX PS DDS implant well characterized&#xD;
      and the same as the currently marketed product. Participants will attend regular visits&#xD;
      during the study at a hospital or clinic. The effect of the treatment will be checked by&#xD;
      questionnaires, medical assessments, and checking for side effects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 7, 2021</start_date>
  <completion_date type="Anticipated">January 12, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 12, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Experiencing Adverse Events (AEs)</measure>
    <time_frame>Up to 7 Days After Study Drug Administration</time_frame>
    <description>An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study.</description>
  </primary_outcome>
  <other_outcome>
    <measure>Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) Updated Applicator Performance</measure>
    <time_frame>Day 1 After Study Drug Administration</time_frame>
    <description>The investigator will evaluate whether the updated DEX PS DDS Applicator dispensed the DEX PS DDS implant in the vitreous cavity and performed as intended, using a treatment administration questionnaire.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">54</enrollment>
  <condition>Macular Edema</condition>
  <arm_group>
    <arm_group_label>Updated Dexamethasone Posterior Segment Drug Delivery System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dexamethasone Posterior Segment Drug Delivery System implant will be administered into the study eye during a single treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Approved Dexamethasone Posterior Segment Drug Delivery System</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dexamethasone Posterior Segment Drug Delivery System implant will be administered into the study eye during a single treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Updated Dexamethasone Posterior Segment Drug Delivery System</intervention_name>
    <description>Intravitreal Administration</description>
    <arm_group_label>Updated Dexamethasone Posterior Segment Drug Delivery System</arm_group_label>
    <other_name>Ozurdex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Approved Dexamethasone Posterior Segment Drug Delivery System</intervention_name>
    <description>Intravitreal administration</description>
    <arm_group_label>Approved Dexamethasone Posterior Segment Drug Delivery System</arm_group_label>
    <other_name>Ozurdex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - Participants with macular edema due to retinal vein occlusion (branch retinal vein&#xD;
        occlusion or central retinal vein occlusion) or diabetic macular edema.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        - Participants with ocular conditions in the study eye for which Dexamethasone Posterior&#xD;
        Segment Drug Delivery System Implant is contraindicated.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ALLERGAN INC.</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ABBVIE CALL CENTER</last_name>
    <phone>844-663-3742</phone>
    <email>abbvieclinicaltrials@abbvie.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Global Research Management /ID# 238944</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91204-2500</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Advanced Eye Centers Inc /ID# 233429</name>
      <address>
        <city>North Dartmouth</city>
        <state>Massachusetts</state>
        <zip>02747-1278</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Retina Research Institute of Texas /ID# 231420</name>
      <address>
        <city>Abilene</city>
        <state>Texas</state>
        <zip>79606-1224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Texas Retina Associates /ID# 231305</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 15, 2021</study_first_submitted>
  <study_first_submitted_qc>July 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2021</study_first_posted>
  <last_update_submitted>October 13, 2021</last_update_submitted>
  <last_update_submitted_qc>October 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Macular Edema</keyword>
  <keyword>Dexamethasone</keyword>
  <keyword>Branch Retinal Vein Occlusion</keyword>
  <keyword>Central Retinal Vein Occlusion</keyword>
  <keyword>Diabetic Macular Edema</keyword>
  <keyword>Noninfectious Uveitis</keyword>
  <keyword>Ozurdex</keyword>
  <keyword>Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.</ipd_time_frame>
    <ipd_access_criteria>Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.</ipd_access_criteria>
    <ipd_url>https://www.abbvie.com/our-science/clinical-trials/clinical-trials-data-and-information-sharing/data-and-information-sharing-with-qualified-researchers.html</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

